The 44th Congress of the Catalan Ophthalmology Society (SCO) begins tomorrow, 28 November. The event, which takes place at the Hotel Barceló Sants, ends on Saturday.
As in previous years, there will be five round tables, with three of them engaged in the discussion of glaucoma. The fourth will be devoted to ocular traumatology and the fifth will deal with the latest developments resulting from vision research.
At 11.30 a.m. on the first day, Dr. Jordi Monés, the Medical Director of the Barcelona Macula Foundation will moderate the Bayer symposium. In addition, Laura Sararols, Lluís Arias and Santiago Abengoechea will present the results and characteristics of the research into the drug Aflibercept and the new EYLEA molecule for the treatment of exudative AMD.
At the same event, Dr. Jaume Català of Sant Joan de Déu Hospital and Dr. Josep Mª Caminal of Bellvitge University Hospital will present “An Update on Ophthalmological Oncology” and will then announce the grants awarded in 2011.
Also attending this edition of the Congress will be Dr. Hussein Muhtaseb, an ophthalmologist specialising in retinal diseases and a Research Fellow at the Barcelona Macula Foundation.